Where can I buy tropical fish in Nanjing?

1. Where can I buy tropical fish in Nanjing?

Tropical fish gift shop

Address: District

Kaiqi tropical fish aquarium equipment supporting center

Address: baixia district, Nanjing, Jiangsu.

gather

Address: near Wubaicun Road, Nanjing

Tel: (025)85 18546 1

subcenter

Address: Gulou District, Nanjing, Jiangsu Province

2. Which is the most promising biological company in India?

Baikang company

The tough personality has made India, the "mother of biotechnology", accumulate huge wealth.

In India, which was still quite closed at that time, women's entrepreneurship paid more hardships than men's entrepreneurship. In order to find a factory, Kailang spent several weeks, because many landlords thought it was unlucky to rent a house to a woman; She couldn't find an employee, so she finally had to beg a female friend to join her company secretly. All the banks refused to lend her $654.38+00,000 start-up capital. Finally, after meeting a banker at a friend's wedding, she was desperate. Her accountant, a man.

exist

Soon after the company opened, it "found another job"; Worst of all, a raw material supplier made an unreasonable and ironic request to Kailang. Unless she hires a male manager, she will never get the materials of their company.

KiranMazumdar-Shaw, 5 1 year old, 1978 made an amazing move in India. She set up a small workshop in her garage and started the experiment of extracting enzyme from papaya ambitiously. At that time, few people in India knew what biotechnology was, but she drew a grand blueprint in her mind: using India's own scientific and technological talents to build a world-class research institution. Today, her company Biocon has become a leader in biotechnology in India. Kailang's wealth has also made a qualitative leap, completing the role transformation from a winemaker to the mother of biotechnology in India-she has become the richest woman in India.

The next goal is to become one of the top five biological companies in the world.

In more than 20 years, Kailang has turned a small enzyme factory into the largest biotechnology company in India. As of the fiscal year of March 3 1 this year, Biocon's operating income was $65,438+$22 million, and its profit was as high as $30.5 million.

In March this year, on the first day of listing, the stock subscription soared 33 times. Today, half a year later, the market value of the company has reached1200 million US dollars. Kailang controls 40% of the company's shares, making her the richest woman in India. Kailang began to aim at the next goal: in the near future, Baikang will rank among the top five biological companies in the world.

A few days ago, Kailang said in an exclusive interview with Newsweek that Baikang has occupied the first place in Asia in terms of market share and operating income, ranking 16 in the world. India's huge biotechnology potential-a large number of high-quality researchers, relatively low cost and clinical research and development skills, provides opportunities for Biocon to participate in international competition.

There is no way to apply for a job and pursue entrepreneurial opportunities.

Kailang was born in an open middle-class family in India. Her father is a famous winemaker in India, although he never drinks. Her mother is a housewife. Unlike many Indian families, Kailang's parents encouraged her to receive more education instead of urging her daughter to get married early. Being impressed by his father's exquisite winemaking technology since he was a child, Kailang also developed a strong interest in winemaking. She got a bachelor's degree in zoology from Bangalore University, and then went to Australia to study. From 65438 to 0975, Kailang hurried back to China after obtaining a master's degree in beer brewing from Ballarat College in Australia, dreaming of becoming the first female brewer in India. However, she is talented but has nowhere to go. The doors of Indian wineries are closed to women. "It was too difficult for women to find jobs," Kailang recalled.

After waiting for two years of work, an accidental opportunity opened the door of Kailang. At that time, BioconBiochemicals, an Irish chemical company, was preparing to enter India. Because Indian law strictly stipulates that foreign investors can only hold 30% shares in Indian investment companies, LeslieAuchincloss, the boss of biochemical company, is eager to find Indian partners. After a period of contact, LeslieAuchincloss found that Kailang was the best partner. "She was so persistent and strong that I thought she would never back down," Auchincloss recalled. When BioconIndia was founded, its initial capital was US$ 6.5438+0 million, and it was planned to produce enzymes for producing beer, wine, paper, animal food and detergent.

Women are discriminated against, and the road to entrepreneurship is full of hardships.

In India, which was still quite closed at that time, women's entrepreneurship paid more hardships than men's entrepreneurship. In order to find a factory, Kailang spent several weeks, because many landlords thought it was unlucky to rent a house to a woman; She couldn't find an employee, so she finally had to beg a female friend to join her company secretly. All the banks refused to lend her $654.38 +0 million start-up capital. Finally, after meeting a banker at a friend's wedding, she was desperate. Her accountant, a man, "looked for another job" shortly after the company opened; Worst of all, a raw material supplier made an unreasonable and ironic request to Kailang. Unless she hires a male manager, she will never get the materials of their company.

She started a business in her own kitchen and successfully extracted an enzyme that can tenderize meat from papaya fruit and a collagen that can make beer more transparent from fish bubbles of tropical fish. This is the beginning of Indian biotechnology industry.

To resolve the crisis, the capital market is good at dancing with long sleeves.

After solving one crisis after another, Baikang finally made a profit of $65.438+0 million in the late 1980s, that is, at this time, Auchincloss sold her 30% shares in the company to Unilever, and Kailang kept her 70% shares. After India relaxed the foreign investment law, Unilever tried to buy Kailang shares and ended in failure. 1997, Unilever sold its chemicals division (including Biocon) to Imperial Chemical Industry Corporation (ICI). However, ICI has no intention to explore the field of drug research. A year later, the company plans to sell its shares in Biocon for $2 million. Kailang seized this rare opportunity and persuaded her husband John Thaw, a former president of a textile company, to sell his property in London and join Baikang Company. (John Thaw is now in charge of the company's global business development, holding 25% of the company's shares. )

This equity transfer made Kailang completely free, and she began to shift from enzyme production and processing to insulin production. Kailang hopes to start with the production of insulin and enter the manufacturing field of other drugs in India, thus opening the door to the United States.

Of course, new business development needs funds. At this time, Kailang has been able to raise enough funds by virtue of its own reputation: ICICIVentures (unrelated to ICI) invested 3 million US dollars to control the company 15%, and the bank borrowed 3 million US dollars from it, with interest ranging from 10% to 12%. Kailang has put all his eggs in one basket. She recalled: "If it fails, the company will only go bankrupt."

Recruit talents to ensure the sustainable development of the company.

200 1 The patent right of lovastatin, an early cholesterol prevention drug, expired, and Biocon obtained the right to sell such generic drugs in the Indian market from the Indian Medicine Administration. This provides an important opportunity for the later development of Biocon. This year, the company also obtained permission from the US Food and Drug Administration, becoming the first Indian company to sell lovastatin in the US market. Today, Biocon has occupied 50% market share of such drugs in the United States. Biocon is not only satisfied with the production of generic drugs, Kailang has recruited 600 scientists to engage in the research and development of patented drugs.

"In the long run, the people-oriented development model will be more sustainable than just building infrastructure," said Kailang, who is now the chairman of the Biotechnology Committee of the Federation of Indian Industries and the chairman and executive director of Biocon.

"Adventurers" will not give up because of outside doubts.

Many countries are arguing about the advantages and disadvantages of developing biotechnology. In particular, European countries oppose the use of genetically modified foods, African countries would rather starve than accept food aid from the United States, and India also refuses the donation of soybeans and corn from the United States.

As the chairman of the Biotechnology Committee of the Federation of Indian Industries, Kailang still strongly advocates that India should cultivate and develop biotechnology under appropriate preventive measures. "India has a population of 1 billion, and14 is still extremely poor, and biotechnology can improve India's diet, agriculture, scientific research and disease treatment. As long as you have technology, you can do anything. "

Indian biotechnology experts are developing potatoes with high protein content and rice with high nutrition to solve the malnutrition problem of the people; They also developed a leprosy vaccine, which was not developed even in western countries; They are also trying to develop biofuels from crops such as sugar cane. The experiment of genetically modified food has potential risks, for example, it may bring new gene fragments into India's staple food rice, thus posing a threat to the human body. Karen thinks these threats are enough to deal with, so some people call her an "adventurer".

Kailang believes that India is a "land of geomantic omen" for clinical trials of biotechnological drugs. India is one of the countries with the largest number of diabetic patients in the world, and there is no clinical data of these patients at present. In addition, a large number of descendants of close relatives in India can be used to study genetic defects; The genomes of various races and tribes also need to be studied. Because of the large number and diversity of patients, we will get a lot of unique data.

Undoubtedly, these ideas have been criticized by many people. These critics believe that this is equivalent to selling India's population resources and threatening India's biodiversity. Kailang thinks these concerns are necessary, but she also tries to convince these critics. She believes that "we can't give up our efforts because we are afraid." Shan Fuchang/Compiled